146 related articles for article (PubMed ID: 16706997)
1. Can the PFA-100 be modified to detect P2Y12 inhibition?
Pidcock M; Harrison P
J Thromb Haemost; 2006 Jun; 4(6):1424-6. PubMed ID: 16706997
[No Abstract] [Full Text] [Related]
2. Multiple electrode aggregometry and P2Y(12) antagonists.
Johnson A; Dovlatova N; Heptinstall S
Thromb Haemost; 2008 Jun; 99(6):1127-9. PubMed ID: 18521523
[No Abstract] [Full Text] [Related]
3. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
4. Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP.
Contreres JO; Dupuy E; Job B; Habib A; Bryckaert M; Rosa JP; Simoneau G; Herbert JM; Savi P; Levy-Toledano S
Br J Haematol; 2003 Feb; 120(4):633-42. PubMed ID: 12588350
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Storey RF; Judge HM; Wilcox RG; Heptinstall S
Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of clopidogrel resistance.
Almsherqi ZA; McLachlan C; Mossop PJ; Deng Y
Thromb Res; 2005; 116(5):451-3. PubMed ID: 16039696
[No Abstract] [Full Text] [Related]
8. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
Srinivasan S; Mir F; Huang JS; Khasawneh FT; Lam SC; Le Breton GC
J Biol Chem; 2009 Jun; 284(24):16108-16117. PubMed ID: 19346255
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Fox SC; Behan MW; Heptinstall S
Cell Calcium; 2004 Jan; 35(1):39-46. PubMed ID: 14670370
[TBL] [Abstract][Full Text] [Related]
10. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
[TBL] [Abstract][Full Text] [Related]
11. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?
van Werkum JW; Kleibeuker M; Mieremet N; ten Berg JM; Hackeng CM
J Thromb Haemost; 2007 Apr; 5(4):884-6. PubMed ID: 17403207
[No Abstract] [Full Text] [Related]
14. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
15. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
Cuisset T; Frere C; Poyet R; Quilici J; Gaborit B; Bali L; Brissy O; Lambert M; Morange PE; Alessi MC; Bonnet JL
Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
[TBL] [Abstract][Full Text] [Related]
17. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
19. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]